坎格雷洛对皮肤冠状动脉干预的周围手术结果的影响:对患者一级数据的综合分析
Philippe Gabriel Steg1, Deepak L Bhatt2, Christian W Hamm3
1Université Paris-Diderot, Sorbonne Paris-Cité, Paris, France; Département Hospitalo-Universitaire FIRE, Hôpital Bichat, AP-HP, INSERM U-698, Paris, France.
Lancet (London, England)
|September 10, 2013
概括
康格罗尔在皮肤冠状动脉干预 (PCI) 期间显著降低了血栓并发症,包括支架血栓形成. 然而,这种益处伴随着轻度出血事件的风险增加.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 干预心脏病学 干预心脏病学
背景情况:
- 康格洛尔是一种静脉注射的血小板抑制剂,用于穿皮冠状动脉干预 (PCI).
- 在PCI中,三项大型随机试验评估了康格罗尔与克洛皮多格雷尔或安慰剂的疗效.
- 这些试验的综合分析提供了关于康格罗尔的有效性和安全性的全面数据.
研究的目的:
- 评估康格罗尔在预防PCI期间和之后发生的血栓性并发症的有效性.
- 在接受PCI的大量患者群体中,将康格罗尔与对照疗法 (克洛皮多格雷尔或安慰剂) 进行比较.
- 评估草的安全概况,特别关注出血事件.
主要方法:
- 从三项试验 (CHAMPION-PCI,CHAMPION-PLATFORM,CHAMPION-PHOENIX) 的患者级数据进行了组合分析.
- 包括24,910名为各种冠状动脉疾病 (STEMI,NSTE-ACS,稳定的CAD) 接受PCI的患者.
- 主要疗效终点:48小时后死亡,心肌梗塞,再血管化或支架血栓形成的综合结果. 主要安全终点:在48小时内严重或危及生命的出血.
主要成果:
- 康格洛尔使初级复合结局降低了19% (3.8%与4.7%相比) 和支架血栓症降低了41% (0.5%与0.8%相比).
- 二次综合结局结果也显示,康格罗尔显著减少,效益维持在30天.
- 在严重出血方面没有显著差异,但使用香草与轻度出血的显著增加有关 (16.8%与13.0%对比).
结论:
- 康格洛尔有效地减少了接受PCI的患者的周围手术血栓并发症.
- 康格罗尔在减少血栓事件方面的好处是显著的,并且在各个患者亚组中一致.
- 与克洛皮多格雷尔或安慰剂相比,使用康格雷罗时增加轻度出血是一个值得注意的安全考虑因素.
相关概念视频
Angina IV: Management
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Cardiac Catheterization I: Pre-Procedure Overview
Cardiac catheterization is an invasive diagnostic technique used to identify and evaluate structural and functional diseases of the heart and major blood vessels. This technique diagnoses congenital heart disease, coronary artery disease, valvular heart disease, and coronary spasms and assesses ventricular function. It helps guide treatment decisions, including the need for revascularization procedures like percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) and...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Acute Coronary Syndrome III: Diagnostic Studies
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...

